Bacillus Calmette-Guérin (BCG), the antituberculosis vaccine, localizes within immature phagosomes of macrophages and dendritic cells (APCs), and avoids lysosomal degradation. BCG-derived antigenic peptides are thus inefficiently processed by APCs, and we investigated alternate mechanisms of Ag processing. Proteomics identified that BCG phagosomes are enriched for nicastrin, APH, and presenilin components of γ-secretase, a multimeric protease. Using an in vitro Ag presentation assay and BCG-infected APCs, we found γ-secretase components to cleave BCG-derived Ag85B to produce a peptide epitope, which, in turn, primed IL-2 release from Ag85B-specific T cell hybridoma. siRNA knockdown or chemical inhibition of γ-secretase components using L685458 decreased the ability of BCG or Mycobacterium tuberculosis-infected APCs to present Ag85B. In addition, L685485 inhibition of γ-secretase led to a decreased ability of BCG-dendritic cells to immunize mice and induce Ag85B-specific CD4 T cells in vivo. Because BCG and M. tuberculosis sequester within APCs preventing immune recognition, γ-secretase components appear to fortuitously process the immunodominant Ag85B, facilitating immune recognition.

Tuberculosis is the leading cause of death from an infectious disease, and bacillus Calmette-Guérin (BCG) is the only approved vaccine against human tuberculosis. BCG gives variable protection against tuberculosis depending on geographic region, and this is likely due to the loss of some immunogenic Ags encoded by the RD1 region, strain variation, and population immunity factors. Th1 immunity defends against tuberculosis and is dependent on the ability of APCs to process peptides from mycobacteria through lysosome- or proteasome-mediated degradation, and epitope presentation through MHC class II (MHC-II) or I (MHC-I), respectively, to CD4 and CD8 T cells. However, BCG vaccine sequesters within immature phagosomes of APCs, which do not fuse with lysosomes (1). Thus, we proposed earlier that BCG-infected APCs would be deficient in presenting MHC-II–dependent peptides to T cells. Initially, we found that phagosomes of BCG had near-neutral pH because of the exclusion of vATPase enzyme; as a consequence, intraphagosomal cathepsin-D (Cat-D) protease was inactive (2). Using a T cell hybridoma specific for the major secreted Ag85B, we then reported that BCG-infected APCs showed decreased Ag presentation (2). Interestingly, wild type Mycobacterium tuberculosis H37Rv phagosomes that also have near-neutral pH again showed reduced Ag presentation compared with the attenuated mutant, M. tuberculosis H37Ra. The wild type M. tuberculosis is the first pathogen reported to evade phagosome–lysosome fusion in macrophages (3). It is now evident that M. tuberculosis has multiple immune evasion mechanisms, and BCG vaccine seems to have inherited similar properties from wild type Mycobacterium bovis, the pathogen of bovine tuberculosis (4).

Tuberculosis is an important disease for which efficient vaccination strategies are required. We therefore investigated alternative mechanisms of Ag processing within macrophages that could lead to immune recognition of mycobacteria. BCG and M. tuberculosis phagosomes purified from macrophages were subjected to proteomic analysis that identified proteins relatively enriched on their phagosomes (5). We found that nicastrin, a component of the multimeric membrane-bound γ-secretase, was enriched on the phagosomes of the wild type M. tuberculosis, and to a lesser extent on BCG vaccine phagosomes. Because γ-secretase has been implicated in proteolysis and thought to recycle phagosomal proteins, we hypothesized that it could cleave mycobacterial phagosome-derived proteins. We demonstrate in this article that nicastrin, presenilin, and anterior pharynx defective-1 (APH) components of γ-secretase generate a peptide epitope from BCG phagosome-derived Ag85B, which is subsequently presented to the T cells. Because this occurred in naive macrophages, we propose that the APCs have a novel, innate mechanism to produce antigenic peptides, which may fortuitously facilitate recognition of immune-evasive mycobacteria.

C57BL/6 mouse bone marrow-derived primary macrophages and dendritic cells (DCs) were cultured and infected with BCG (Pasteur) or wild type M. tuberculosis (both from ATCC) as previously described (6, 7). They were overlaid with BB7 T cells (1 APC:20 T cells) specific for Ag85B (kind gift of Dr. Harding, Case Western Reserve University), and IL-2 secreted in response to Ag was quantitated using ELISA. Blockade of γ-secretase was carried out using specific small interfering RNA (siRNA) sets (Supplemental Fig. 1) (Santa Cruz Biotechnology and Invitrogen) against nicastrin, APH, and presenilin. siRNA knockdown was carried out for 4 h followed by resting cells for 18 h before experimentation. siRNAs were a mix of two or three duplexes, and the controls were scrambled siRNA supplied also by the manufacturer (SCB). Transfection was done using the transfectamine kit supplied by SCB (sc-29528). The effect of siRNA or L685458 on the surface expression of MHC-II, CD80, and CD86 among APCs was tested using flow cytometry as described earlier (8) (Supplemental Fig. 2). Peptide VANNTRLWVYCGNGTP was used to spike treated or untreated APCs, to measure direct presentation by APCs to BB7 T cells (7).

APCs were infected with gfpBCG or gfpM.tuberculosis (H37Rv), washed, fixed, counterstained, and scored for immunofluorescence colocalization with primary Abs and isotypes for each of the γ-secretase components as per published procedures (2, 9, 10) (Supplemental Fig. 2). All fluorescent anti-Ig conjugates were further absorbed with killed BCG suspension to avoid nonspecific binding.

To assess organelle (phagosome)-mediated Ag presentation versus APC-mediated presentation after L685458 treatment, BCG phagosomes or inert latex beads (3-μM diameter) phagocytosed into APCs were purified using sucrose gradients as per previously standardized methods and estimated for protein content (8). Pellets of phagosomes estimated to contain 5 μg/ml protein were gently sonicated to disperse, checked by microscopy, mixed with BB7 T cells (106 T cells per 5 μg pellet of phagosomes in triplicate wells per experiment), and supernatants collected after 4 h were estimated for IL-2.

Macrophages were treated or not with L685458 in 24-well plates, infected with BCG, and washed. Monolayers were washed with PBS, extracted with 0.05% digitonin, 0.5% sucrose in PBS-EDTA buffer for 15 min for cytosol fraction, which was then ultrafiltered and estimated for protein. The monolayer was washed with cold 0.05% digitonin, 0.5% sucrose in PBS-EDTA three times, and the membrane fraction was solubilized with 0.1% Triton X-100 in PBS for 15 min, estimated for protein, and stored until Western blot analysis. Phagosomes localize into the membrane fractions in primary APCs (9).

BCG-infected DCs were used as vaccines per protocols described previously (10). Bone marrow-derived cells were cultured in DMEM with GM-CSF (10 ng/ml; Invitrogen) for 7 d, and column-purified DCs (CD11c beads from Miltenyi) were infected before or after treatment with L685458 (15 and 100 μM/106 DCs; 4 h) with BCG. The DCs were washed, and 2 × 106 DCs/mouse were injected i.p. into C57BL/6 mice (4 mice/group; 2 experiments). Untreated DCs injected into mice were negative controls. Viability of DCs before and after treatment was confirmed to be >90% using LDH release assay. After 2 wk, spleens were removed and IFN-γ+ CD4 T cells were detected using flow cytometry for intracellular cytokines, and by ELISPOT analysis with Ag85B restimulation (10). All animal procedures were conducted under approved institutional protocols.

Our proteomic study showed enrichment of nicastrin on wild type M. tuberculosis phagosomes, whereas others showed similar enrichment on BCG phagosomes (5, 11). Using immunofluorescence analysis, we identified the three γ-secretase components, relative to BCG phagosomes within APCs. Using in situ colocalization with deconvolution microscopy, we found Abs to nicastrin, APH, and presenilin to stain the phagosomes, with minimal speckled stain around the perinuclear zone (Fig. 1A, 1B). The positive control Ab LAMP1 stained most BCG phagosomes, whereas the isotype control did not stain a significant number of phagosomes (Fig. 1B).This observation was consistent with the Western blot profiles of BCG-infected primary macrophages, where the three components of γ-secretase were enriched on membrane fractions compared with cytosol (Fig. 1C, left panel). Membrane fractions of siRNA (SCB)-treated, BCG-infected macrophages were similarly tested using Western blotting. Specific siRNA knockdown reduced the levels of γ-secretase components compared with scrambled control sequence (Fig. 1C, right panel). In addition, BCG phagosomes purified from macrophages using sucrose gradients were found to have enzymatically active γ-secretase. They cleaved the amyloid precursor protein into an 87-kDa product (Fig. 1D). Similar studies were performed using DCs with identical results (not shown).

FIGURE 1.

Macrophages infected with mycobacteria colocalize with γ-secretase components. Abs to γ-secretase stain phagosomes with less cytoplasmic localization. A, C57BL/6 mouse bone marrow-derived macrophages were infected with M. bovis BCG vaccine strain tagged with gfp (gfpBCG) and stained with an Ab to nicastrin, APH, or presenilin. Shown are three color panels for nicastrin and merged images for APH and presenilin, followed by Texas Red conjugates (original magnification ×1000). B, Phagosomes colocalizing with γ-secretase components were scored using Ab stains and deconvolution microscopy (one of three similar experiments, ±SD). Isotype Ab did not stain phagosomes, and gfpBCG in DCs showed a similar pattern (not shown). Membrane versus cytosolic distribution of γ-secretase. C, Treated or untreated BCG-infected macrophages were fractionated into membrane and cytosol fractions and tested using Abs and Western blots. Left panel, Untreated fractions: γ-secretase components are enriched in membranes. Right panel, Treated fractions: siRNA knockdown reduces the levels of γ-secretase components in the membrane fractions, compared with knockdown with scrambled sequence. D, γ-Secretase is active on the phagosomes. BCG phagosomes purified from treated or untreated macrophages were incubated in buffer to determine the cleavage of amyloid precursor protein into an 87-kDa APP product (arrow).

FIGURE 1.

Macrophages infected with mycobacteria colocalize with γ-secretase components. Abs to γ-secretase stain phagosomes with less cytoplasmic localization. A, C57BL/6 mouse bone marrow-derived macrophages were infected with M. bovis BCG vaccine strain tagged with gfp (gfpBCG) and stained with an Ab to nicastrin, APH, or presenilin. Shown are three color panels for nicastrin and merged images for APH and presenilin, followed by Texas Red conjugates (original magnification ×1000). B, Phagosomes colocalizing with γ-secretase components were scored using Ab stains and deconvolution microscopy (one of three similar experiments, ±SD). Isotype Ab did not stain phagosomes, and gfpBCG in DCs showed a similar pattern (not shown). Membrane versus cytosolic distribution of γ-secretase. C, Treated or untreated BCG-infected macrophages were fractionated into membrane and cytosol fractions and tested using Abs and Western blots. Left panel, Untreated fractions: γ-secretase components are enriched in membranes. Right panel, Treated fractions: siRNA knockdown reduces the levels of γ-secretase components in the membrane fractions, compared with knockdown with scrambled sequence. D, γ-Secretase is active on the phagosomes. BCG phagosomes purified from treated or untreated macrophages were incubated in buffer to determine the cleavage of amyloid precursor protein into an 87-kDa APP product (arrow).

Close modal

The proteolytic activity of γ-secretase is known and was found enriched on inert latex bead phagosomes of macrophages. It was proposed that γ-secretase could be involved in recycling and remodeling of phagosome proteins (12). Interestingly, both BCG vaccine and wild type M. tuberculosis secrete Ag85B and other immunogenic proteins that accumulate within the phagosomes (1315). Furthermore, Ag85B has a major T cell epitope and is a powerful immunogen for mice and humans, either vaccinated with BCG or infected with M. tuberculosis (14). MHC-II–dependent presentation of a peptide epitope of Ag85B from mycobacteria-infected APCs has been shown to induce IL-2 secretion from Ag85B-specific T cell hybridoma in several studies (2, 6, 7). We therefore hypothesized that mycobacterial phagosome-derived Ag85B could be accessed and cleaved by γ-secretase components, and this event was measurable in vitro.

Because a specific chemical inhibitor for γ-secretase (L685458) has been used to block nicastrin activity, we initially tested the effect of L685458 on Ag presentation by APCs infected with the BCG vaccine. Fig. 2 shows that L685458 had a significant, dose-dependent, inhibitory effect on Ag presentation by both macrophages and DCs. Flow cytometry showed that L685458 did not affect the surface expression of MHC-II, CD80, or CD86 (Supplemental Fig. 2). Furthermore, when the Ag85B peptide was added to such cells, direct peptide presentation was comparable.

FIGURE 2.

BCG-infected APCs present mycobacterial Ag85B to T cells and the process is inhibited by protease inhibitors. Macrophages (white bars) and DCs (black bars) from C57BL/6 mouse bone marrow were treated or not with γ-secretase inhibitor L-685485 or Cat-D inhibitor pepstatin, followed by infection with BCG and Ag presentation to BB7 T cell hybridoma, specific for mycobacterial Ag85B. T cells were overlaid on macrophages (1:20) for 4 h and supernatants measured for IL-2 using ELISA. L685485 and pepstatin both show a dose-dependent inhibition of Ag presentation, and their combination (L+P) is additive at 100-μM dose (one of three similar experiments, ±SD; IL-2 values of all treated groups versus untreated, p < 0.009, t test).

FIGURE 2.

BCG-infected APCs present mycobacterial Ag85B to T cells and the process is inhibited by protease inhibitors. Macrophages (white bars) and DCs (black bars) from C57BL/6 mouse bone marrow were treated or not with γ-secretase inhibitor L-685485 or Cat-D inhibitor pepstatin, followed by infection with BCG and Ag presentation to BB7 T cell hybridoma, specific for mycobacterial Ag85B. T cells were overlaid on macrophages (1:20) for 4 h and supernatants measured for IL-2 using ELISA. L685485 and pepstatin both show a dose-dependent inhibition of Ag presentation, and their combination (L+P) is additive at 100-μM dose (one of three similar experiments, ±SD; IL-2 values of all treated groups versus untreated, p < 0.009, t test).

Close modal

We previously reported that phagosomal Ag85B production could occur because of the action of Cat-D and pepstatin: an inhibitor of cathepsin proteases inhibited Ag presentation. To further determine whether both Cat-D and γ-secretase contributed to Ag85B epitope production, we blocked APCs with pepstatin to inhibit Cat-D and L685458 to inhibit γ-secretase. Fig. 2 indicates that each agent inhibited peptide presentation and their combination had an additive effect. Pepstatin either alone or in combination did not affect the surface expression of MHC-II, CD80, or CD86 (data not shown). We therefore propose that Cat-D, an intraphagosomal, acid pH-dependent protease, and membrane-bound γ-secretase, which works best at neutral pH, both produce Ag85B-derived peptide in and around the phagosomes.

Nicastrin and presenilin have been reported to possess protease activity on their own (16). To further evaluate whether γ-secretase components vary in their protease activity, we conducted siRNA knockdown experiments. APCs were treated or not with siRNA against nicastrin, APH, and presenilin, followed by BCG or M. tuberculosis infection and Ag presentation. Fig. 3A (BCG) and Fig. 3B (wild type M. tuberculosis) show that siRNA knockdown of γ-secretase components affected Ag presentation by APCs infected with BCG and M. tuberculosis. Control scrambled siRNA had no significant effect on Ag presentation. siRNA probes from two different sources had comparable effects on Ag presentation (Fig. 3, Supplemental Fig. 3). Furthermore, BCG phagosomes but not inert latex beads purified from L685458-treated or untreated macrophages were able to present Ag85B to BB7 T cells. L685458 significantly suppressed Ag presentation (Fig. 3C).

FIGURE 3.

Functional blockade of γ-secretase inhibits Ag presentation in APCs. APCs were treated or not with siRNA against γ-secretase components, followed by infection with either BCG (A) or M. tuberculosis (H37Rv strain) (B), and Ag presentation and IL-2 assay using ELISA. The siRNA knockdown of nicastrin, presenilin, and APH affects Ag presentation (one of three similar experiments, ±SD, p values shown above bars for comparison with the untreated group; t test). C, Phagosomes directly present Ag85B, which is inhibited by L685458. BCG phagosomes from L685458-treated or untreated macrophages were purified on sucrose gradients and incubated with BB7 T cells (106 T cells per 5 μg phagosome protein) followed by ELISA for IL-2 (one of two similar experiments, ±SD, p values shown above bars for comparison with the untreated group; t test).

FIGURE 3.

Functional blockade of γ-secretase inhibits Ag presentation in APCs. APCs were treated or not with siRNA against γ-secretase components, followed by infection with either BCG (A) or M. tuberculosis (H37Rv strain) (B), and Ag presentation and IL-2 assay using ELISA. The siRNA knockdown of nicastrin, presenilin, and APH affects Ag presentation (one of three similar experiments, ±SD, p values shown above bars for comparison with the untreated group; t test). C, Phagosomes directly present Ag85B, which is inhibited by L685458. BCG phagosomes from L685458-treated or untreated macrophages were purified on sucrose gradients and incubated with BB7 T cells (106 T cells per 5 μg phagosome protein) followed by ELISA for IL-2 (one of two similar experiments, ±SD, p values shown above bars for comparison with the untreated group; t test).

Close modal

We previously demonstrated that DCs infected with BCG vaccine elicit immune responses in mice after vaccination, which are protective against subsequent challenge with virulent tuberculosis (10). Furthermore, Ag85B protein or its DNA vaccine offers significant protection against tuberculosis in mice. These two concepts provided a model to examine the effect of γ-secretase–mediated Ag85B-epitope production on the immunogenicity of BCG-infected DCs. DCs were treated or not with L685458, infected with BCG, and injected into mice. Two weeks later, splenic T cells were assayed for Ag85B-specific responses of T cells secreting IFN-γ, using flow cytometric analysis and ELISPOT analysis of spleens. Fig. 4A illustrates that DCs infected with BCG elicited markedly better IFN-γ+ CD4 T cell response in mouse spleens compared with L685458-treated DCs with BCG. Similarly, ELISPOT analysis of corresponding spleens showed that L685458-treated DCs induced lesser numbers of Ag85B-specific CD4 T cells (Fig. 4B). These data strongly suggest that γ-secretase plays a significant role in generating a peptide epitope from phagosome-associated Ag85B, and this event helps immune recognition of mycobacteria, which are otherwise sequestered within macrophages and DCs.

FIGURE 4.

γ-Secretase inhibitor L-685458 decreases the ability of DCs to prime T cells in vivo. CD11c bead purified DCs from C57BL/6 mouse bone marrow were left untreated, treated with a low (15 μM per 106 DCs) or high dose (100 μM per 106 DCs) of γ-secretase inhibitor L-685458, followed by infection with BCG. Washed and viable DCs were injected i.p. to naive mice. Two weeks later, spleen T cells were analyzed for IFN-γ producing CD4 T cells using flow cytometry (A) and Ag85B-specific T cells using ELISPOT (B) (p values, t test; two experiments).

FIGURE 4.

γ-Secretase inhibitor L-685458 decreases the ability of DCs to prime T cells in vivo. CD11c bead purified DCs from C57BL/6 mouse bone marrow were left untreated, treated with a low (15 μM per 106 DCs) or high dose (100 μM per 106 DCs) of γ-secretase inhibitor L-685458, followed by infection with BCG. Washed and viable DCs were injected i.p. to naive mice. Two weeks later, spleen T cells were analyzed for IFN-γ producing CD4 T cells using flow cytometry (A) and Ag85B-specific T cells using ELISPOT (B) (p values, t test; two experiments).

Close modal

Because wild type M. tuberculosis and BCG vaccine sequester within immature phagosomes of APCs avoiding lysosomal degradation, mechanisms of peptide-mediated priming of T cells have been thought to be suboptimal during tuberculosis or vaccination. Sequestration enables M. tuberculosis to be immune-evasive, whereas BCG would become less immunogenic (17). Until recently, however, the mechanistic basis of immune sequestration remained unclear. Significantly, two studies proposed a new concept that phagosomes themselves are capable of assembling peptide epitopes into MHC-II and MHC-I for eventual presentation to T cells. Harding’s group demonstrated that the immunodominant, secreted Ag85B is cleaved and presented by mycobacterial phagosomes (6). However, mycobacterial phagosomes from human macrophages were also found capable of presenting peptides through MHC-I (18, 19).

Because Ag85B is by itself highly immunogenic and used as a vaccine, we addressed the mechanisms of in situ epitope generation using BCG-infected macrophages and Ag85B-specific T cell hybridoma (20, 21). Although several proteases were found at trace levels, Cat-D was found markedly enriched in BCG phagosomes. Using siRNA knockdown studies, we then demonstrated that Cat-D–mediated proteolysis leads to Ag85B-derived peptide epitope, which, in turn, primes BB7 T cells. However, the efficacy of Cat-D, an acid pH-dependent aspartic acid protease was reduced because of the near-neutral pH of the BCG phagosome lumen. We also reported that BCG excluded the acidifying enzyme, vacuolar proton ATPase relative to M. tuberculosis H37Ra, and the phagosomes of the latter had more active Cat-D. As a consequence, macrophages infected with M. tuberculosis H37Ra were better able to activate BB7 T cells to secrete IL-2. We therefore concluded that intraphagosome generation of Ag85B epitope is regulated by the pH. This is consistent with the known mechanism of peptide production in lysosomes where the acidifying enzyme vATPase reduces the pH to activate several proteases. Unexpectedly, the proteomics of BCG phagosomes revealed the presence of γ-secretase, and in this study, we demonstrated that phagosome-associated Ag85B is also processed by γ-secretase. Our studies therefore propose a novel observation that mycobacterial phagosomes have at least two mechanisms of peptide generation, one of which is acid pH dependent and the other is a membrane-associated, acid pH-independent process.

This model appears consistent with the known cell biology of BCG vaccine and M. tuberculosis phagosomes. Although BCG and M. tuberculosis pathogen have adapted to survive in an intracellular niche avoiding the lysosome, the host seems to have adapted to deliver proteases into phagosomes to facilitate immune recognition. Although the characterization of membrane-bound γ-secretase has been difficult, Jutras et al. proposed that it may perform a physiological function of recycling phagosome proteins (12, 16). We propose that during this natural recycling process, γ-secretase fortuitously produces peptide epitopes from bacteria enclosed within phagosomes. There is an intriguing possibility that γ-secretase may also produce shorter peptide fragments, and downstream events may channel them toward the CD8 pathway. It is conceivable that it may also cleave proteins from other intraphagosomal pathogens.

We therefore propose that APCs have an innate mechanism to generate immune signals from mycobacterial phagosomes that otherwise remain evasive. It is pertinent to note in this article that strategies to bypass immune sequestration have generally enhanced the immunogenicity of BCG vaccine. Thus, expression of a pH-independent, active Cat-S in BCG led to increased Ag85B presentation by macrophages infected with recombinant BCG–Cat-S (22). Expression of the recombinant pore-forming toxin listeriolysin in BCG enabled Ags to leak into cytosol across the phagosome membrane and enhanced the ability of recombinant BCG-LLO to induce CD8 T cells in mice (23). Finally, enhanced localization of BCG into autophagolysosomes through rapamycin treatment of APCs led to increased Ag85B presentation and enhanced immunogenicity in mice (10, 23, 24).

The enrichment of nicastrin on mycobacterial phagosomes was initially identified using proteomics of phagosomes (5, 11). These studies highlighted that the mycobacterial phagosomes are complex structures that contain several hundred proteins and the daunting task of functional characterization. This study illustrates the use of a system biology approach to dissect the function of a phagosome-associated protein. We anticipate that a similar dissection of other novel phagosome proteins will lead to a better understanding of mycobacterial immunogenicity.

We thank Dr. C. Harding (Case Western Reserve University) for BB7 T cells and Dr. Dhandayuthapani (Regional Academic Center, University of Texas Health Sciences Center at San Antonio, Edinburg, TX) for the gfpBCG strain.

This work was supported by National Institutes of Health Grant AI78420 (to C.J.). C.R.S. was supported by National Institute of Allergy and Infectious Diseases, National Institutes of Health Grant T32-AI055449 (to S.J. Norris, Principal Investigator).

The online version of this article contains supplemental material.

Abbreviations used in this article:

APH

anterior pharynx defective-1

BCG

bacillus Calmette-Guérin

Cat-D

cathepsin-D

DC

dendritic cell

MHC-I

MHC class I

MHC-II

MHC class II

siRNA

small interfering RNA.

1
Via
L. E.
,
Deretic
D.
,
Ulmer
R. J.
,
Hibler
N. S.
,
Huber
L. A.
,
Deretic
V.
.
1997
.
Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7.
J. Biol. Chem.
272
:
13326
13331
.
2
Singh
C. R.
,
Moulton
R. A.
,
Armitige
L. Y.
,
Bidani
A.
,
Snuggs
M.
,
Dhandayuthapani
S.
,
Hunter
R. L.
,
Jagannath
C.
.
2006
.
Processing and presentation of a mycobacterial antigen 85B epitope by murine macrophages is dependent on the phagosomal acquisition of vacuolar proton ATPase and in situ activation of cathepsin D.
J. Immunol.
177
:
3250
3259
.
3
Armstrong
J. A.
,
Hart
P. D.
.
1971
.
Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes.
J. Exp. Med.
134
:
713
740
.
4
Russell
D. G.
2001
.
Mycobacterium tuberculosis: here today, and here tomorrow.
Nat. Rev. Mol. Cell Biol.
2
:
569
577
.
5
Rao
P. K.
,
Singh
C. R.
,
Jagannath
C.
,
Li
Q.
.
2009
.
A systems biology approach to study the phagosomal proteome modulated by mycobacterial infections.
Int. J. Clin. Exp. Med.
2
:
233
247
.
6
Ramachandra
L.
,
Noss
E.
,
Boom
W. H.
,
Harding
C. V.
.
2001
.
Processing of Mycobacterium tuberculosis antigen 85B involves intraphagosomal formation of peptide-major histocompatibility complex II complexes and is inhibited by live bacilli that decrease phagosome maturation.
J. Exp. Med.
194
:
1421
1432
.
7
Ramachandra
L.
,
Smialek
J. L.
,
Shank
S. S.
,
Convery
M.
,
Boom
W. H.
,
Harding
C. V.
.
2005
.
Phagosomal processing of Mycobacterium tuberculosis antigen 85B is modulated independently of mycobacterial viability and phagosome maturation.
Infect. Immun.
73
:
1097
1105
.
8
Katti
M. K.
,
Dai
G.
,
Armitige
L. Y.
,
Rivera Marrero
C.
,
Daniel
S.
,
Singh
C. R.
,
Lindsey
D. R.
,
Dhandayuthapani
S.
,
Hunter
R. L.
,
Jagannath
C.
.
2008
.
The Delta fbpA mutant derived from Mycobacterium tuberculosis H37Rv has an enhanced susceptibility to intracellular antimicrobial oxidative mechanisms, undergoes limited phagosome maturation and activates macrophages and dendritic cells.
Cell. Microbiol.
10
:
1286
1303
.
9
Daniel
D. S.
,
Dai
G.
,
Singh
C. R.
,
Lindsey
D. R.
,
Smith
A. K.
,
Dhandayuthapani
S.
,
Hunter
R. L.
 Jr
,
Jagannath
C.
.
2006
.
The reduced bactericidal function of complement C5-deficient murine macrophages is associated with defects in the synthesis and delivery of reactive oxygen radicals to mycobacterial phagosomes.
J. Immunol.
177
:
4688
4698
.
10
Jagannath
C.
,
Lindsey
D. R.
,
Dhandayuthapani
S.
,
Xu
Y.
,
Hunter
R. L.
 Jr
,
Eissa
N. T.
.
2009
.
Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells.
Nat. Med.
15
:
267
276
.
11
Lee
B. Y.
,
Jethwaney
D.
,
Schilling
B.
,
Clemens
D. L.
,
Gibson
B. W.
,
Horwitz
M. A.
.
2010
.
The Mycobacterium bovis bacille Calmette-Guerin phagosome proteome.
Mol. Cell. Proteomics
9
:
32
53
.
12
Jutras
I.
,
Laplante
A.
,
Boulais
J.
,
Brunet
S.
,
Thinakaran
G.
,
Desjardins
M.
.
2005
.
Gamma-secretase is a functional component of phagosomes.
J. Biol. Chem.
280
:
36310
36317
.
13
Mustafa Abu
S.
,
Al-Attiyah
R.
.
2003
.
Tuberculosis: looking beyond BCG vaccines.
J. Postgrad. Med.
49
:
134
140
.
14
Wiker
H. G.
,
Harboe
M.
.
1992
.
The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis.
Microbiol. Rev.
56
:
648
661
.
15
Harth
G.
,
Lee
B. Y.
,
Wang
J.
,
Clemens
D. L.
,
Horwitz
M. A.
.
1996
.
Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis.
Infect. Immun.
64
:
3038
3047
.
16
Esler
W. P.
,
Kimberly
W. T.
,
Ostaszewski
B. L.
,
Ye
W.
,
Diehl
T. S.
,
Selkoe
D. J.
,
Wolfe
M. S.
.
2002
.
Activity-dependent isolation of the presenilin-gamma-secretase complex reveals nicastrin and a gamma substrate.
Proc. Natl. Acad. Sci. USA
99
:
2720
2725
.
17
Pancholi
P.
,
Mirza
A.
,
Bhardwaj
N.
,
Steinman
R. M.
.
1993
.
Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages.
Science
260
:
984
986
.
18
Grotzke
J. E.
,
Harriff
M. J.
,
Siler
A. C.
,
Nolt
D.
,
Delepine
J.
,
Lewinsohn
D. A.
,
Lewinsohn
D. M.
.
2009
.
The Mycobacterium tuberculosis phagosome is a HLA-I processing competent organelle.
PLoS Pathog.
5
:
e1000374
.
19
Lewinsohn
D. M.
,
Grotzke
J. E.
,
Heinzel
A. S.
,
Zhu
L.
,
Ovendale
P. J.
,
Johnson
M.
,
Alderson
M. R.
.
2006
.
Secreted proteins from Mycobacterium tuberculosis gain access to the cytosolic MHC class-I antigen-processing pathway.
J. Immunol.
177
:
437
442
.
20
Vordermeier
H. M.
1995
.
T-cell recognition of mycobacterial antigens.
Eur. Respir. J. Suppl.
20
:
657s
667s
.
21
Ganguly
N.
,
Siddiqui
I.
,
Sharma
P.
.
2008
.
Role of M. tuberculosis RD-1 region encoded secretory proteins in protective response and virulence.
Tuberculosis (Edinb.)
88
:
510
517
.
22
Soualhine
H.
,
Deghmane
A. E.
,
Sun
J.
,
Mak
K.
,
Talal
A.
,
Av-Gay
Y.
,
Hmama
Z.
.
2007
.
Mycobacterium bovis bacillus Calmette-Guérin secreting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages.
J. Immunol.
179
:
5137
5145
.
23
Hess
J.
,
Miko
D.
,
Catic
A.
,
Lehmensiek
V.
,
Russell
D. G.
,
Kaufmann
S. H.
.
1998
.
Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes.
Proc. Natl. Acad. Sci. USA
95
:
5299
5304
.
24
Hoft
D. F.
,
Blazevic
A.
,
Abate
G.
,
Hanekom
W. A.
,
Kaplan
G.
,
Soler
J. H.
,
Weichold
F.
,
Geiter
L.
,
Sadoff
J. C.
,
Horwitz
M. A.
.
2008
.
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.
J. Infect. Dis.
198
:
1491
1501
.

The authors have no financial conflicts of interest.